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The local effects of intracutaneous injections into hu-
mans of 1-3 nmol of five products of arachidonic acid 
metabolism, leukotrienes (LT) C4, D." E." a nd B4 from the 
5-lipoxygenase pathways and prostaglandin (PG) D2 
from the cyclooxygenase pathway, were assessed clini-
cally and histologically. In equimolar concentrations, 
LTC4, LTD4, and LTE4 elicited erythema and wheal for-
mation, in which a wheal with central pallor was present 
up to 2 hr, and the erythema p ersisted as long as 6 hr. 
PGD2 elicited a wheal that lasted up to 1 hr and erythema 
that lasted up to 2 hr. The dermal vascular site s affected 
by LTD4 and PGD2 included capillaries, superficial and 
deep venules, and arterioles. L TB4 elicited a transient 
wheal and flare, followed in 3-4 hr by induration that 
was characterized by a d e rmal infiltrate comprise d pre -
dominantly ofneutrophils. The combination ofLTB4 and 
PGD2 elicited tenderness and increased induration as-
sociated with a more intense neutrophil infiltration. 
Thus, the products of the 5-lipoxygenase pathway of 
arachidonic acid m e tabolism in nanomole amounts can 
induce cutaneous vasodilation with e d ema forma tion 
and a neutrophil infiltrate, and these responses are en-
hanced by a cyclooxygenase pathway product, PGD2 • 
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The oxidative products of arachidonic acid appearing with 
physiologic and pathobiologic per turbations of cellular mem-
brane phospholipids include the prostaglandins, throm boxane, 
a nd t he leukotrienes. P rostagla ndin (PG) D 2, the predominant 
product of arachidonic acid metabolism in human mast cells in 
vi tro [1,2] and in vivo [3,4], a nd leukotrienes (LT ) C., D., and 
K, [5-9], recognized as components of slow reacting substance 
of anaphylaxis (SRS-A) , are considered among the mediators 
of acute allergic processes. 
Knowledge of the cutaneous effects of the L T components of 
SRS-A is limited to observations of alterations in venular 
permeability in guinea pigs [6,10,11] and rats [11], but not 
ra bbits [11], a nd the morphologic dem onstration of dilated 
superficial and deep blood vessels in monkey skin (12). PGD2, 
a metabolite of the cyclooxygenase pathway of arachidonic 
acid, can produce vasodilation in rat skin and elicit a wheal and 
erythema r eaction in human skin (13). L TB4, a potent che-
moattractant [14] that elicits a neutrophil inflltrate in monkey 
skin [15], is inactive in the rabbit skin unless combined with a 
vasodila ting prostaglandin (16). Inasmuch as there is no infor-
mation on the cutaneous effects in humans of the leukotrienes 
alone or in combination with PGD 2, the intracutaneous injec-
tion of LTG" LTD., L TK" PGD 2, and L T B. alone and in some 
combinations was assessed by clinical and histologic paJ'am e-
tel's. 
MATERIALS AND METH ODS 
LTG" LTD., LTE., , PGDz, and LT B., were prepared as previously 
described [8,17-20] and stored frozen at a concentration of 25 /Lg/ m l in 
0.1 M phosphate buffe r (pH 6.8l :ethanol (4:1, v/ v) under argon un til 
the day of use. Immediately before inj ection these substances were 
dried under argon and then redissolved in 0. 1 ml of a sterile solu tion 
containing 0.15 M NaCI wi th 2% ethanol.. LT G, (1.0 nmol/site), LTD" 
(1.0 nmol/site), LTE., (1.0 nmol/site) , PGD2 (3.0 nmol/site) , LTB. (1.6 
nmol/site), and vehicle alone or in vaJ·ious comb.inations were coded 
and injected intradermally into the ventral aspects of the forear ms of 
3 adult ma le volunteers after informed consent was obtained. Clinical 
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manifestations were recorded, and the reactions were quantitated by 
measuring their greatest diameter in millimeters at 7 time poin ts from 
10 min to 6 hr; neither the subject nor the recorder had specific 
knowledge of the material administered to a site. 
Preliminary dose-response studies were conducted with LTD., (0.1, 
0.2, and 1.0 nmol/site) in each of the 3 subjects in order to determine 
the single amount and the times of observation to be used for further 
studies. Although each of the three amounts of LTD., elicited erythema 
and wheal formation , the persistence of these manifestations was sub-
stantially greater at 1..0 nmol/site, and thus th is a mount was used for 
further studies of LTG" LTD" and L TE,. 
Skin biopsy specimens were obtained from sites injected with vehicle 
at 2 or 6 hr; with PGD2 at 0.5, 2 and 6 hr; with LTD .. at 2 hr; with LTR, 
at 6 hI'; and with L TB. plus PGD2 at 6 hr. Trephine biopsy specimens 
measuring 4 mm were taken from a skin site after the periphery at the 
four quadrants had been injected with 1% lidocaine without epineph-
r ine. T he tissue was bisected and fixed for 18 hI' at 4°C in solu tion 
composed of 2% paraforma ldehyde, 2.5% glu tara ldehyde, a nd 0.025% 
CaCh in 0.1 M cacodylate buffer, pH 7.4. This fixed tissue was washed 
in the same buffer, postfixed in osmium tetroxide, and embedded in 
E pon. One-micrometer sections were prepared and stained with Giemsa 
diluted 1:10 in 2% Na borate solu tion and examined with a Leitz Dialux 
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FIG 1. Erythema occurring after the in tracutaneous injections of 
LTC. (_) , LTD .. (e), LTE" (A), LTB .. (~), PGD2 (0 ), and saline vehicle 
(0) in 3 subjects. The initia l observations were made at 10 min to 
minimize the nonspecific effects of injection. The greatest diameter of 
the clinical lesions is depicted in mm on the ordinate. 
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FIG 2. Wheal formation occulTing after the in tracutaneous injec-
tions of LTC .. ,(_) , LTD .. (e) , LTE .. (A) , LTB .. (~) , PGD2 (0 ), and saline 
vehicle (0 ) in 3 subjects. The greatest dia meter of the clinical lesions 
is depicted in mm on the ordinate. 
20 microscope at magnifications up to x1000 [21-23]. The cells were 
counted, and the number of infiltrating cells per total biopsy specimen 
was determined by subtracting the cells in the specimens from sites 
receiving vehicle alone from the total cells; results were expressed as 
net cells/mm" of 1-l-Im thick tissue sections. 
Neutrophils in the dermis were defined by morphologic cri teria 
including multilobed nuclei and a finely granular blue-gray cytoplasm. 
Activation of endothelial cells of the venules was defined by enlarge-
ment of both cytoplasmic and nuclear mass and by the presence of a 
prominent nucleolus in a nucleus with loose chromatin and basophilic 
staining of the nucleoplasm. 
RESULTS 
Clinical Cutaneous Responses 
Each of the three SRS-A leukotrienes, LTC .. , L Tnl, and 
LTE" (1.0 nmol/site), elicited erythema that blanched with 
pressure and wheal formation in each subject (Figs 1, 2). Tran-
sient buming was noted in each subject after the injections of 
LTD, and L TE" but not after LTC,. After the injections of 
LTC. , LTD., and L TE., the center of the wheal was pale and 
the erythema was Jess intense than it was at the periphery and 
beyond the wheal. The lack of erythema over the wheal was 
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more prominent with LTG, and L Tn, than with L TE •. The 
erythema appeared by 10 min, peaked at 1 hr, and was not 
dissipated by 4 hr; wheal formation was noted at 10 min, peaked 
at 1 hr, and was dissipated by 4 ill·. The injection of the saline 
vehicle did not elicit a wheal or flare reaction during the period 
of observation from 10 min to 6 hr. 
PGD2 (3.0 nmol/site) elicited eryth ema t hat blanched with 
pressure and a wheal (Figs 1, 2) without occurrence of symp-
toms. The erythema over the wheal was of th e sam e intensity 
as that occurring beyond th e wheal. Erythema appeared at 10 
min, peaked at 30-60 min, and was dissipated by 4 hr. A wheal 
appeared at 10 min, peaked at 30 min, and was dissipated by 2 
hr. 
LTB. (1.6 nmol/site) elicited transient erythema that 
blanched with pressure and wheal formation in only 1 of 3 
subjects (Figs 1, 2). L TB. caused induration as a firm 3-mm 
papule without tenderness in the same subject at 6 hr. The 
combination of L TB" and PGD2 produced a prolonged ery-
thema of 6 hI' duration and a wheal that becam e tender at 2 hr 
and indurated as a firm 5-mm papule by 4 hr in each subject. 
Histologic A lterations 
Skin biopsy specimens obtained 2 hr after t he injection of 
LTD .. (1.0 nmol/site) (Fig 3) in each of 3 subjects exhibited 
dermal edem a and marked a nd uniform dilation of capillaries 
and superficial and deep venules with activation of endoth elial 
cells, as well as dilation of som e arterioles. Biopsy specimens 
obtained 0.5 (Fig 4) and 2 hr after t he injection of PGD~ (3.0 
nmol/site) exhibited dermal edema a nd m arked and uniform 
dilation of capillaries and superficial and deep venules wit h 
activation of endothelial cells, as well as dilation of some 
arterioles. By 6 ill· a diminution in the degree of dilation of the 
superficial and deep venules was noted. L Tn, at 2 hr elicited 
12.8 neutrophils/mm2 in 1 of 3 subjects (Table I, Fig 3). Al-
though PGDz elicited a transient perivenular neutrophil infil-
trate at 0.5 ill· in each of 3 subjects, ranging from 32.6 to 295.4 
cells/mm2, neutrophils were not noted at th e 2-ill· time point. 
FIG 3. Histologic response occurring after the intracutaneous injec-
tion of LTD., (1.0 nmol/site) at 2 hr in subject 3. Note erythrocytes 
within dilated dermal venule and perivenular neutrophils (1-j.tm thick 
Epon-embedded specimen; Giemsa; X 252). 
r 
FIG 4. Histologic response OCCUlTing after the in tracutaneous injec-
tion of PGD2 (3.0 nmol/site) at 0.5 hr in subject 3. Note erythrocytes 
within c!ilated dermal venule and perivenu lar neutrophils (l -j.tm thick 
Epon-embedded specimen; Giemsa; x 252) . 
'I' ABLE I. Qua.ntita.tion of infiltrating cells in shin 
T ime after in - Neutrophils (net celIS/ 111m' ) Molecule jection (h r) Subject 1 Subject 2 Subject 3 
LTD., 2 0 0 12.8 
PGDz 0.5 295.4 170.7 32.6 
PGDz 2 0 0 0 
PGD, 6 0 38.4 663.9 
LTB .. 6 169.3 44.7 440.1 
LTB .. + PGD2 6 651.0 905.0 513.3 
At the 6-ill· time point neutrophils were again present in 2 of 3 
subjects, ranging from 38.4 to 663.9 neutrophils/ mm2. 
Biopsy specimens obtained at 6 ill· after the injection of L TB .. 
(1.6 nmol/site) (Fig 5) exhibited perivenular inflitrating neutro-
phils in each subject, ranging from 44.7 to 440.1 cells/ mmz 
(Table I) without dilation of superficial and deep venules and 
arterioles. T he combination of LTR, and PGDz evoked a syn-
ergistic increase in neutrophil numbers in 2 of 3 subjects. Fibrin 
was deposited in interstitial array in 2 of 3 subjects after th e 
injection of LTB" (Fig 5) and was not increased after the 
combination with PGD2 . Dermal edema was not. observed. 
DISCUSSION 
The pathobiologic effects occurring after the intracutaneous 
administration of the oxidative products of arachidonic acid 
metabolism known to be generated by immediate-type hyper-
sensitivity reactions differed in th e char acter of the erythema 
and wheal responses to PGD~ and the 6-sulfidopeptide leuko-
trienes. The administration of 1.0 nmol of LTC., LTn" a nd 
LTE. and 3.0 nmol of PGD2 elicited an erythema and wheal 
response that was well developed by 10 m in (Figs I , 2), the 
point at which the wheal associated with injection of the control 
site h ad subsided. The wheal elicited by the 6-sulfidopeptide 
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FIG 5. Histologic response occurring after the intracutaneous injec-
tion of LTB, (1.6 nrhol/site) at 6 hr in subj ect 1. Note neutrophil 
infiltration and fibrin deposition (I-pm thick Epon-embedded specimen; 
Giemsa; X 196.9). 
leukotrienes exhibited a pale center as compared to the ery-
thema at its periphery and to the eryth ema extending beyond 
the wheal. The wheal persisted for more than 2 hr, and the 
erythema continued to be prominent at 6 hr. The erythema and 
wheal response to PGD2 differed in that the intensity of the 
erythema was uniform over and about the wheal, and the 
duration of both the erythema and wheal was less than one-
half that observed with the 6-sulfidopeptide leukotrienes. 
The basis for the differences in clinical morphology in the 
lesions elicited by PGD2 as compared to the 6-sulfidopeptide 
leukotrienes was not apparent either from studies of biopsy 
specimens can-ied out at the peak of wheal formation, 0.5 hr for 
PGD2 and at 2 hr for LTD" or from a comparison at 2 hr when 
the response elicited by PGD2 had subsided. The degree of 
dermal edema was compatible with the magnitude of the clin-
ical response, and the microvascular changes consisting of di-
lation of capillaries and superficial and deep venules and some 
arterioles were not different in intensity or uniformity (Figs 3, 
4). The constriction of the cutaneous microvasculature in guinea 
pig skin occurring after the injection of 6-sulfidopeptide leuko-
trienes [6,10,U] has been demonstrated by a decreased local 
blood flow measured by isotopic and dye extravasation tech-
niques and is associated with an increase in venular permeabil-
ity, as indicated by the leakage of protein-bound blue dye. · 
These findings are compatible with the visual observation that 
the application of 6-sulfidopeptide leukotrienes to the hamster 
cheek pouch causes constrict jon of terminal arterioles followed 
by -extravasation of protein-bound fluorescent dye into the 
surrounding tissues [24]. The clinical wheal and dermal edema 
observed in human skin reflect the augmentation of venular 
permeability. The erythema relates to the dilation of the mi-
crovasculature, and the presumptive arteriolar constriction 
would accoUllt for the central pallor of the leukotriene-induced 
wheal, and would not be expected to be maintained in the 
biopsy specimen. 
The prevailing view that vasodilation and augmentation of 
venular permeability are prerequisites for the in vivo chemo-
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tactic response to a chemotactic factor [25] is supported by the 
synergistic interaction between L TB. and PGD2 in 2 of 3 
subjects. Although 3.0 nIDol of PGDz did not elicit a clinical 
response that was maintained at 6 hr (Figs 1, 2) as noted in an 
earlier study [13], the microvasculature was still dilated in 
biopsy specimens. LTB. (1.6 nmol) alone caused a transient 
wheal in a single subject (Fig 2) and the development of a 
nontender, indurated, 3.0-mm papule at 6 hr; when combined 
with PGD2 , L TB. caused a tender, indurated 5.0-mm papule 
that appeared at 4 hr in each subject. The clinical synergy 
between L TB, and PGD2 was supported by morphologic find-
ings in 2 of 3 subjects. In these subjects, quantitative neutrophil 
counts (Table I) were increased 4- and 10-fold over the additive 
effect of each agent alone. In the third subject, the clinical 
synergy was not confrrmed by a quantitative increase in neutro-
phil number. The PGD2-initiated n eutrophil accumulations 
were subclinical as compared to the effects of LTB., possibly 
because only the effects of the latter agonist included fibrin 
deposition. Inasmuch as PGD2 has been demonstrated to be a 
chemokinetic factor in vitro [26], it could be argued that its 
combination with the chemotactic factor LTB. was synergistic 
in terms of the neutrophil as a target cell, in addition to 
providing the necessary alterations in the microvasculature. 
Moreover, these interactive effects may have clinical impor-
tance in that the inhibition of the cyclooxygenase pathway by 
nonsteroidal anti-inflammatory agents could be beneficial or 
detrimental depending on the responses of cells to the altered 
array of products produced. 
The authors acknowledge the expert technical assistance of Eleanor 
Manseau in preparing the histologic specimens. 
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3,4-Dihydroxybenzylamine: An Improved Dopamine Analog Cytotoxic 
for Melanoma Cells in Part Through Oxidation Products Inhibitory to 
DNA Polymerase 
GEORGE B. FITZGERALD, PH.D. AND MICHAEL M. WICK, M.D., PH.D. 
Division of Medicine, S idney Farber Cancer Institute, and Departments of Dermatology and Biological Chemistl)', Harvard Medical School, 
Boston, MassacJwsett.~, U.S.A. 
The dopamine analog 3,4-dihydroxybenzylamine (3,4-
DHBA), a novel antitumor agent, was shown to inhibit 
directly DNA polymerase in cells of the deeply pig-
mented murine melanoma, S -91A, p ermeabilized to nu-
cleotides by lysolecithin. In contrast, levodopa and do-
pamine did not inhibit DNA polymerase in permeabilized 
cells in the absence of exogenous tyrosinase. Analysis 
using isolated DNA polymerase showed that the inhibi-
tory activity of the ortho dihydroxy compounds was 
totally d e p endent upon enzymatic activation. The enzy-
matic activation of the ortho derivative 3,4-DHBA by 
tyrosinase results in two reactive species: a semiquinone 
intermediate and a less reactive quinone. Inhibition of 
DNA polymet'ase by activated 3,4-DHBA was shown by 
dialysis and kinetic studies to involve an irreversible 
reaction which occurs at two inhibitor interaction sites 
as determined by a H ill plot analysis. Double-stranded 
DNA protected the enzyme from inhibition by 3,4-DHBA, 
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Abbreviations: 
3,4-DHBA: 3,4-dihyd.roxybenzylamine 
DTE: di thioeryt.hritol 
IC",,: concentration resulting in 50% inhibi tion of enzyme 
RT: reverse lranscl'iptase 
s uggesting that the inhibitory s ites are at or near the 
template-initiator binding site. 
Levodopa, dopamine, and the therapeutically superior ana-
log, 3,4-dihydroxybenzylamine (3,4-DHBA) have been shown 
to be effective ant itumor agents in a variety of experimental 
melanoma tumors [1-3]. Recently, preliminary studies have 
suggested that these agents ar e capable of inhibiting replication 
in huma n melanoma and are in a clinical trial [4,5]. 
The inj t ial studies with these drugs revealed that th ey in-
hjbi ted thymidine incorporation in vitro, while having minimal 
effects on RNA or protein synthesis [1,2]. It appeared that the 
immediate cellular effect of th ese catechols was a direct and 
selective inhibition of DNA synthesis. Further studies demon-
strated that these drugs, in the presence of th e polyphenol 
oxidase, tyrosinase (which catalyzes th e oxidation of tyrosine 
to melanin in melanocytes), are capable of inhibiting sulfhydryl-
dependen t DNA polymerases [3,4]. We have recently reported 
a detailed analysis with the sulfhydryl-dependent enzyme, re-
verse transcriptase (RT), which showed that active oxidation 
by tyrosinase produces a more reactive intermediate- semiqui-
none-than either the completely reduced or oxidized forms of 
3,4-DHBA [6]. The findings of Mason et al [7], and more 
recently, Felix and Sealy [8], which demonstrate by electron 
spin resonance that o-benzosemjquinones are formed by tyro-
sinase oxidation of catechols, support tllis concept of a llighly 
reactive intermediate inhibi tory species. 
We ,have extended our studies of the inhibitory action of 3,4-
DHBA to the enzym e, DNA polym erase 0 ', which is likely to be 
